Tuesday, 16 February 2021

Overactive Bladder Treatment Market Opportunity Analysis-2027

 

Overactive Bladder Treatment Market Dynamics

High prevalence of overactive bladder is expected to propel the Overactive Bladder Treatment Market growth over the forecast period. Moreover, increasing awareness about the importance of diagnosis and treatment of the disease is a key factor leading to increase in number of patients treated for overactive bladder.

Furthermore, increasing number of drug development programs for overactive bladder is expected to fuel the overactive bladder treatment market growth, by adding new drug in the market. Currently, generic drugs such as cholinergic receptor inhibitors are available for treatment of the condition. Therefore, development and approval of new drug entity with better drug profile is expected to boost the market growth.

For instance, in 2018, Urovant Sciences—a biopharmaceutical company that focuses on developing novel therapy for urologic conditions—entered in phase III clinical trial for its drug —Vibegron —an oral Beta-andrenergic agonist for indication of overactive bladder treatment.

Furthermore, Taris Biomedical LLC—entered phase II clinical trials for its drug candidate TAR-302 for the treatment of overactive bladder. TAR 302 is a trospium chloride-based continuous local therapy, which is expected to efficiently aid in treatment of overactive bladder with few side effects.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2007

Key players operating in the market are focused on development of combinational therapies. For instance, in 2017, Astellas Pharma, Inc. received supplemental New Drug Application (sNDA) from FDA for conditional therapy of mirabegron and solifenacin succinate for the treatment of urinary incontinence.

Overactive bladder is a common medical condition where there is sudden urge of urination. Overactive bladder is sometimes coupled with urine leakage, condition known as incontinence. Millions of people across the globe suffers from overactive bladder and it is more common in old age people.

Urine leakage and frequent urination are the main symptoms of overactive bladder. The frequency of urination in the patient is around eight times a day. Moreover, frequent urination during sleep hours is common in such patients. Overactive bladder is commonly diagnosed by tests such as urine culture, bladder scan, cystoscopy or urodynamic testing.

Robust drug pipeline with drugs in phase II and phase III clinical trials, soon expected to be in the market, are expected to drive the overactive bladder treatment market growth. However, alternate therapies such as the neuromodulation therapy which includes sacral neuromodulation and percutaneous tibial nerve stimulation to deliver electric impulse to nerve, are expected to hinder the overactive bladder treatment market growth.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/overactive-bladder-treatment-market-2007

Overactive Bladder Treatment Market - Regional Analysis

The global overactive bladder treatment market is segmented into six regions that include, North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America overactive bladder treatment market holds dominant position amongst other regions, owing to high prevalence of overactive bladder in the region. For instance, according to the journal Current Bladder Dysfunction Reports, 2016 review, millions of people suffer from overactive bladder in the U.S. and estimates continuous increase in cost of overactive bladder management. However, increasing awareness about the disease in Asia Pacific regions is expected to boost the regional Asia Pacific overactive bladder treatment market growth in the region, over the forecast period at a fast rate.

Overactive Bladder Treatment Market – Competitive Analysis

Key players operating in the overactive bladder treatment market include, Janssen Pharmaceuticals Inc., Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Barr Laboratories Inc. (subsidiary of Teva Pharmaceuticals), Alembic Pharmaceuticals Ltd., Pfizer Inc., Astellas Pharma Inc., Endo International PLC, and Invagen Pharmaceuticals Inc.

Key players operating in the market are focusing on leveraging their expertise to develop novel treatment therapies for the disease, to enhance their market share. For instance, in 2017, UroGen Pharma Ltd .a clinical-stage biopharmaceutical company in collaboration with Allergan Pharmaceuticals International Limited entered in phase II clinical trial for RTGel in combination with BOTOX, for overactive bladder treatment. RTGel is a hydrogel-based proprietary formulation of UroGen Pharma Ltd.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2007

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


No comments:

Post a Comment